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Abstract
The first total synthesis of (+)-gliocladin B is described. Our concise and enantioselective
synthesis takes advantage of a new regioselective Friedel–Crafts-based strategy to provide an
efficient multigram-scale access to the C3-(3′-indolyl)hexahydropyrroloindole substructure, a
molecular foundation present in a significant subset of epipolythiodiketopiperazine natural
alkaloids. Our first-generation solution to (+)-gliocladin B involved the stereoselective formation
of (+)-12-deoxybionectin A, a plausible biosynthetic precursor. Our synthesis clarified the C15
stereochemistry of (+)-gliocladin B and allowed its full structure confirmation. Further studies of a
versatile dihydroxylated diketopiperazine provided a concise and efficient synthesis of (+)-
gliocladin B as well as access to (+)-gliocladin C.
Introduction
Epipolythiodiketopiperazine alkaloids are a structurally diverse class of secondary fungal
metabolites that display a wide spectrum of biological activity including antibiotic,
antifungal, antiviral, and cytotoxic effects.1,2 These mycotoxins are characterized by a
bridged polysulfide linkage across the cyclic dipeptide substructure.3,4,5,6,7
Epipolythiodiketopiperazines with a 3′-indolyl substitution at the C3 position of a
cyclotryptophan constitute an intriguing subset of this alkaloid family (Fig. 1).8,9 (+)-
Gliocladin B (1),10,11 a new epidithiodiketopiperazine, and (+)-gliocladin C (4), an atypical
non-thiolated triketopiperazine, were first isolated by Usami in 2004 from a strain of
Gliocladium roseum OUPS-N132. (+)-Gliocladins exhibit significant cytotoxic activity
against the murine P388 lymphocytic leukemia cell line.10a In 2007, Overman reported the
first enantioselective synthesis of (+)-gliocladin C (4) and confirmed its stereochemical
assignment.12a Recently, Overman reported a concise and elegant second-generation
synthesis of (+)-gliocladin C (4) and its utility in the synthesis of the related
epidithiodiketopiperazine (+)-gliocladine C.12b The most recent synthesis of (+)-gliocladin
C (4), reported by Stephenson, used photoredox catalysis to introduce an indolyl
substructure as a key step.12c Although Usami and co-workers’ studies allowed them to
elucidate the molecular structure of (+)-gliocladins,10a limitations in spectroscopic
techniques did not permit stereochemical assignments of (+)-gliocladins A (2) and B (1) at
C15.11 As an epipolythiodiketopiperazine alkaloids,7 we initiated a program to develop a
broadly applicable strategy toward C3-(3′-indolyl)hexahydropyrroloindoles, an endeavor
culminating in the first total synthesis of (+)-gliocladin B (1) and its complete
stereochemical assignment.
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Exciting progress has been made toward the concise construction of C3sp3–Csp213,14 and
C3sp3–Csp37,15,16,17 linkages as well as C3sp3–N18 junctions in cyclotryptamine-based
alkaloids. Inspired by seminal reports on the chemistry of functional
hexahydropyrroloindoles19 by Crich and Danishefsky,20 several of our reported synthetic
strategies have focused on the preparation and functionalization of 3-
bromocyclotryptamine16a and 3-bromocyclotryptophan7,14,16b-c derivatives. Intrigued by the
molecular structure of C3-(3′-indolyl)hexahydropyrroloindole alkaloids, we sought a
versatile synthetic strategy for the introduction of the C3-(3′-indoyl)-substituent into
complex polycyclic diketopiperazines. Notably, the direct alkylative cyclization of
tryptamine derivatives with indole was described by Somei to result in a mixture of
regioisomers.21 Recently, it was reported12c that 3-bromocyclotryptophans could be
functionalized under basic conditions with a variety of nucleophiles.18e,i However, indole-
nucleophiles exclusively led to N-alkylation to give C3-(N-indoyl)-products.18c
Interestingly, free-radical based strategies for the derivatization of 3-bromocyclotryptophans
have also been described for introduction of the 3′-indolyl substructure.12c,22 Herein, we
report a direct, scalable regio- and stereoselective Friedel–Crafts-based indolylation of C3-
bromopyrrolidino-indoline fused to a diketopiperazine. The versatility of this new C3sp3–
C3′sp2 bond formation in conjunction with our methodologies for late-stage
diketopiperazine dihydroxylation7 and directed thiolation chemistry7b allowed for a concise
and stereocontrolled route to (+)-gliocladin B (1) in addition to offering access to (+)-
gliocladin C (4, Scheme 1).
Results and discussion
Retrosynthetic analysis
To date, four monomeric bis(thiomethylether)diketopiperazines with a C 3-(3′-indolyl)-
substituent have been isolated from different fungi.8b-c,10a In each case, due to the absence
of solid-state structure data or critical nOe correlations, the stereochemistry of the C15-
methyl sulfide remained undefined. In two cases, the bis(thiomethyl)ethers were isolated
from the same fungal strain alongside their corresponding epidisulfides (i.e., {(+)-bionectin
C (2)23/(+)-bionectin A (6)}8e and {(+)-T988 B (3)/(+)-T988 C (10)}8b), prompting the
authors to postulate a cis configuration. We envisioned the sulfides might arise from
irreversible trapping of the corresponding epipolysulfides by reductive S-methylation along
the biosynthetic pathway.24 Thus, we postulated that (+)-gliocladin B (1) could
biosynthetically arise from the corresponding bridged epidithiodiketopiperazine, namely
(+)-12-deoxybionectin A (11, Scheme 1). This approach would enable stereoselective
introduction of the cis-configured bis(thiomethyl) ethers for comparison with the
spectroscopic data for natural (+)-gliocladin B (1).10a
In deference to our desire for a maximally concise and unified strategy en route to (+)-
gliocladin B (1), (+)-gliocladin C (4) and (+)-12-deoxybionectin A (11), and consistent with
our hypothesis for their biogenesis, our retrosynthetic plan was designed as illustrated in
Scheme 1. Recognizing the potential versatility of hexacyclic diol 12 as a common precursor
to these three alkaloids, we planned to access the epidisulfide and the corresponding
methylsulfides via late-stage stereoselective thiolation. This approach would also offer a
chance to examine the conversion of (+)-12-deoxybionectin A (11) into (+)-gliocladin B (1),
a transformation of plausible biogenetic relevance. Furthermore, we envisioned the
conversion of diol 12 into (+)-gliocladin C (4) using an oxidation-dehydration sequence. The
synthesis of the key hexacyclic diol 12 was predicated on application of our dihydroxylation
chemistry to hexacyclic diketopiperazine 13. In view of the inherent nucleophilicity of
indoles and grounded on our previous studies on the formation of related C3sp3–Csp2
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linkages,14 we sought a general solution to C3-(3′-indolyl)diketopiperazine alkaloids (Fig.
1) via a stereoretentive Friedel–Crafts alkylation of endo-tetracyclic bromide 15.25
First-generation total synthesis of (+)-gliocladin B
Our unified synthesis of (+)-gliocladins B (1) and C (4) commenced with the
bromocyclization of diketopiperazine (−)-16 (Scheme 2),7,16b accessible in three steps from
commercially available N-Boc-L-tryptophan and sarcosine methyl ester on greater than 10-
gram scale.26 Exposure of diketopiperazine (−)-16 to molecular bromine in dichloromethane
at 0 °C afforded endo-tetracyclic bromide (+)-17 with a high level of diastereoselection
(endo:exo, ~97:3)26 in 75% yield (endo-diastereomer). After significant experimentation, we
discovered that exposure of bromide (+)-17 to indole (14a, Table 1, entry 1) in the presence
of silver tetrafluoroborate27 in nitromethane28 at 0 °C yielded the desired cis-fused 3′-
indolyl adduct in 37% yield along with three undesired regioisomers (i.e., 2 ′-, 5′-, 6′-
indolyl). We next investigated the influence of the steric and electronic properties of the
nucleophile on the efficiency of the indolylation reaction. While the use of various N-alkyl
or N-carbamate indole derivatives had minimal effect on the outcome of the indolylation, a
marked increase in regioisomeric ratio (rr) was observed with N-triisopropylsilylindole
(14b, Table 1, entry 2). Addition of 2,6-di-tert-butyl-4-methylpyridine (DTBMP) as a
Brønsted acid scavenger prevented undesired protodesilylation. Notably, the use of 5-
bromoindole (14c, Table 1, entry 3) further enhanced the desired regioselectivity as well as
the isolated yield. Ultimately, 5-bromo-1-triisopropylsilylindole (14d, Table 1, entry 4)
proved to be an excellent nucleophile for the desired regio- and stereoselective Friedel–
Crafts-type coupling. Significantly, coupling of bromide (+)-17 with indole 14d promoted
by AgBF4 in nitroethane readily afforded the desired 3-(3′-indolyl)hexahydropyrroloindole
(+)-19d in 83% yield on a 5-gram scale (Scheme 2).
Having established an expeditious synthetic solution to the 3-(3′-
indolyl)hexahydropyrroloindole intermediate (+)-19d, we proceeded to evaluate our planned
unified synthetic strategy to alkaloids (+)-1, (+)-4, and (+)-11 (Scheme 1). Accordingly, a
quantitative single-flask conversion of adduct (+)-19d to the corresponding derivative
(+)-19a set the stage for chemoselective oxidation and access to the branching point diol
(−)-20 (Scheme 2). The desired dihydroxylation of (+)-19a at C11-methine and C15-
methylene positions to give diol (−)-20 proved exceptionally challenging. Ultimately,29 we
achieved the critical and challenging dihydroxylation of substrate (+)-19a with tetra-n-
butylammonium permanganate30 (n-Bu4NMnO4, 3.8 equiv) in dichloromethane,31
providing diol (−)-20 in 41% yield as a single diastereomer. Interestingly, the use of
substoichiometric amount of oxidant typically resulted in the isolation of the C11-α-
isomeric alcohol as the partial oxidation product, consistent with our observations regarding
the reactivity profile of these diketopiperazines.7
Armed with the critical diol (−)-20, we proceeded from this strategic point of divergence
with our planned stereoselective thiolation7b en route to (+)-gliocladin B (1, Scheme 2).
Exposure of diol (−)-20 to trifluoroacetic acid in hydrogen sulfide-saturated
dichloromethane solution at 0 °C generated the corresponding thiohemiaminal 22 in a highly
diastereoselective fashion (>10:1 dr) via trapping of iminium ion 21 from its less hindered
concave face. Removal of the volatiles followed by addition of isobutyryl chloride and
pyridine in dichloromethane afforded hexacyclic thioisobutyrate (+)-23 in 82% yield over
two steps. The regio- and diastereoselective monothiolation of diol (−)-20 to afford C11-β-
thiol 22 is consistent with the anticipated innate preference for faster iminium ion formation
at C11 as compared to C15. Exceptional control in the thiolation was achieved by
stereoinduction from the proximal C3-stereocenter. While our initial conditions for
desulfonylation of the sensitive intermediate (+)-23 to give aniline (+)-24 proved
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capricious,32 the use of an aqueous sodium ascorbate–ascorbic acid mixture in combination
with UV irradiation at 350 nm reliably afforded the desired aminothioisobutyrate (+)-24 in
57% yield. Hydrazinolysis of both thioester and ester functional groupings followed by
chemoselective S-sulfenylation with triphenylmethanesulfenyl chloride gave the sensitive
disulfide (+)-25 in 81% yield over two steps.7b,33
Under optimal conditions, taking advantage of the high oxophilicity34 and low
thiophilicity35 of hafnium trifluoromethanesulfonate (Hf(OTf)4), we accomplished the
critical cyclization of triphenylmethanedisulfide (+)-25 (Scheme 2) to the corresponding
epidisulfide via the putative C15 iminium ion 26 and concomitant loss of triphenylmethyl
cation.7b Gratifyingly, exposure of intermediate (+)-25 to Hf(OTf)4 in acetonitrile provided
(+)-12-deoxybionectin A (11) in 80% yield.36 Ultimately, reduction of the bridgehead
disulfide with NaBH4 followed by in situ S-methylation37 afforded (+)-gliocladin B (1) in
80% yield. All 1H and 13C NMR data26,38 as well as the optical rotation {[α]D24 = +200 (c
0.062, CHCl3); for lit. [α]D16 = +200 (c 0.06, CHCl3)} for our synthetic (+)-gliocladin B (1)
matched those provided in the isolation report,10a confirming the molecular structure of this
mycotoxin. Furthermore, the relative and absolute configurations of (+)-1 were proven by
X-ray crystallographic analysis, and its thermal ellipsoid representation (Scheme 2)26
revealed the pseudoaxial and cis configuration of the two thiomethyl ethers.39
Second-generation total synthesis of (+)-gliocladin B
Our original strategy toward (+)-gliocladin B (1), based on the regio- and stereospecific
thiolation of key diol (−)-20 followed by sulfenylation and ring closure, resulted in
bridgehead disulfide (+)-11, thus confirming the cis configuration and chemically hinting at
the viability of its biosynthetic connection with (+)-12-deoxybionectin A (11). With an
unambiguous structural confirmation of (+)-gliocladin B (1) through our synthetic study, we
next sought to develop a more streamlined route to (+)-1. Relying on the versatility of diol
(−)-20, exposure to sodium thiomethoxide and trifluoroacetic acid in nitromethane resulted
in the formation of bis(thiomethyl)ether (+)-27 (Scheme 3) with a good level of
diastereoselection (C15β:C15α, ~7:1)26 in 77% yield (single diastereomer), consistent with
the steric bias imposed by the C3-(3′-indolyl)-substituent. Interestingly, this approach can
be extended to related alkyl thiols. N1-Benzenesulfonyl photodeprotection gave (+)-
gliocladin B (1) in 68% yield over two steps. Not only did the nucleophilic bisthiolation
proceed with good diastereoselection, but this second-generation route also provided an
expedient route to (+)-1 in 10% yield over nine steps.
Total synthesis of (+)-gliocladin C
The atypical triketopiperazine (+)-gliocladin C (4) likely arose from further metabolization
of the epipolythiodiketopiperazine motif.40 Overman’s concise syntheses12a,b of (+)-(4)
established its stereochemical assignment and optical activity. Recognizing diol (−)-20 as a
strategic intermediate in the synthesis of C3-(3′-indolyl)hexahydropyrroloindole alkaloids,
we next aimed to exploit its potential as a precursor of (+)-gliocladin C (4) through C11-
dehydration followed by selective C15-oxidation (Scheme 4). Accordingly, site-selective
silylation of the more accessible C15 hemiaminal followed by photolytic desulfonylation
gave aniline (+)-29 in 87% yield over two steps. Interestingly, exposure of aminoalcohol
(+)-29 to trifluoroacetic anhydride and 2,6-di-tert-butyl-4-methylpyridine in acetonitrile
resulted in N1-tri-fluoroacetylation concomitant with C11-dehydration to generate 65
enamide (−)-30 in 88% yield. Removal of the silyl ether followed by oxidation with o-
iodoxybenzoic acid in DMSO41 provided fragile triketopiperazine 32. Treatment with acetic
acid in aqueous acetone gave (+)-gliocladin C (4) in 54% yield over three steps. All 1H
and 13C NMR data26 as well as the optical rotation {[Δ]D25 = +126 (c 0.08, MeOH); for lit.
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[α]D16 = +115 (c 0.6, MeOH)}12a for our synthetic (+)-gliocladin C (4) were identical in all
respects with literature data.10a,12
Conclusions
We have developed an effective synthetic strategy to access the 3-(3′-
indolyl)hexahydropyrroloindole substructure, a motif present in several complex
epipolythiodiketopiperazine alkaloids. Our mild and highly regioselective Friedel–Crafts-
based coupling strategy led to the efficient construction of the desired C3sp3–C3′sp2 linkage
on multi-gram scale, affording the first concise and enantioselective synthesis of (+)-
gliocladin B (1). Our first-generation solution resulted in the stereoselective synthesis of
epidithiodiketopiperazine (+)-12-deoxybionectin A (11) , a plausible biosynthetic precursor
to (+)-gliocladin B (1), culminating in its structure confirmation and stereochemical
assignment. Relying on the versatility of dihydroxylated diketopiperazine (−)-20, we also
developed a highly concise and unified strategy resulting in a second-generation synthesis of
(+)-gliocladin B (1, nine steps, 10% overall yield) as well as access to (+)-gliocladin C (4).
This new synthetic strategy that allows an advanced stage union between an indole and a
cyclotryptamine fused to a diketopiperazine combined with our methods for stereoselective
sulfuration is expected to provide access to other 3-(3′-indolyl)-
epipolythiodiketopiperazines.
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Fig. 1.
Representative natural C3-(3′-indolyl)hexahydropyrroloindole alkaloids.11
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Scheme 1.
Retrosynthetic analysis of (+)-gliocladin B (1), (+)-gliocladin C (4), and (+)-12-
deoxybionectin A (11).
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Scheme 2.
First-generation total synthesis of (+)-gliocladin B (1). Reagents and conditions: (a) Br2,
CH2Cl2, 0 °C (75%); (b) AgBF4, DTBMP, EtNO2, 0 °C (83%, 5g-scale); (c) H2, Pd/C,
NEt3, MeOH, EtOAc, 23 °C; Et3N•3HF, 23 °C (100%); (d) n-Bu4NMnO4, CH2Cl2, 23 °C
(41%); (e) H2S, TFA–CH2Cl2 (1:9 v/v), 0 °C; i-PrCOCl, pyr, CH2Cl2, 0→23 °C (82%, 2-
steps); (f) hν (350 nm), 1,4-dimethoxynaphthalene, ascorbic acid, sodium ascorbate, H2O,
MeCN, 25 °C (57%); (g) N2H4, THF, 0 °C; Ph3CSCl, NEt3, THF, 0 °C (81%, 2-steps); (h)
Hf(OTf)4, MeCN, 23 °C (80%); (i) NaBH4, MeI, pyr, MeOH, 23 °C (80%); DTBMP = 2,6-
di-tert-butyl-4-methylpyridine, TFA = trifluoroacetic acid, i-PrCOCl = isobutyryl chloride,
pyr = pyridine.
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Scheme 3.
Second-generation total synthesis of (+)-gliocladin B (1). Reagents and conditions: (a)
MeSNa, TFA–MeNO2 (1:1 v/v), 0→23 °C (77%); (b) hν (350 nm), 1,4-
dimethoxynaphthalene, ascorbic acid, sodium ascorbate, H2O, MeCN, 25 °C (88%).
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Scheme 4.
Total synthesis of (+)-gliocladin C (4). Reagents and conditions: (a) TIPSCl, DMAP,
CH2Cl2, 23 °C (95%); (b) hν (350 nm), 1,4-dimethoxynaphthalene, ascorbic acid, sodium
ascorbate, H2O, MeCN, 25 °C (92%); (c) TFAA, DTBMP, MeCN, 23 °C (88%); (d)
(HF)•pyr, THF, 23 °C; (e) IBX, DMSO, 23 °C; (f) AcOH, H2O, acetone, 23 °C (54%, 3-
steps); TIPSCl = triisopropylsilyl chloride, DMAP = 4-(dime-thylamino)pyridine, TFAA =
trifluoroacetic anhydride, IBX = o-iodoxybenzoic acid.
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